Genomic Health (GHDX) Q4 Revenue Tops Views, Offers Guidance

Genomic Health (NASDAQ: GHDX) reported Q4 EPS of $0.23, may not compare to the analyst estimate of $0.30. Revenue for the quarter came in at $104.6 million versus the consensus estimate of $101.51 million.

GUIDANCE:

Genomic Health sees FY2019 EPS of $1.38-$1.54, versus the consensus of $1.25. Genomic Health sees FY2019 revenue of $436-448 million, versus the consensus of $438.82 million.

For earnings history and earnings-related data on Genomic Health (GHDX) click here.

You May Also Be Interested In

• BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Investing.com’s stocks of the week